Current Epidemiology of the General Anesthesia Practice for Cesarean Delivery Using a Nationwide Claims Database in Japan: A Descriptive Study

Hiroshi Yonekura 1,2,*, Yusuke Mazda 3, Shohei Noguchi 3, Hironaka Tsunobuchi 2 and Motomu Shimaoka 1

Abstract: The current status of general anesthesia practice for cesarean delivery in Japan remains unknown. Therefore, using a nationwide claims database, we aimed to investigate general anesthesia use for cesarean delivery over a period of 15 years, and to analyze the general anesthesia practice in Japan. Patients who claimed the Japanese general anesthesia claim code (L008) for cesarean delivery between 1 January 2005, and 31 March 2020, were analyzed. Primary endpoint was the prevalence of general anesthesia use. We used two definitions of general anesthesia: L008 code only (insurance definition) and combination of the L008 code with muscle relaxant use (clinical definition). The general anesthesia claim cohort (L008) included 10,972 cesarean deliveries at 1111 institutions from 2005 to 2020. Muscle relaxants were used in 27.3% of L008 claims cases. The rate of general anesthesia use for cesarean delivery ranged from 3.9% in clinical definition to 14.4% in insurance definition of all cesarean deliveries. We observed a temporal trend of gradual decrease in general anesthesia use, regardless of its definition (p for trend < 0.001). We recommend the clinical definition of general anesthesia as the combination of L008 code and muscle relaxant use in a claims-based approach.

Keywords: administrative database; cesarean delivery; general anesthesia; obstetric anesthesia

1. Introduction

In the Japanese perinatal care delivery system, there are over 2500 medical facilities for approximately 1 million deliveries per year, of which 18.6% were cesarean deliveries [1,2]. Compared to Western countries, the Japanese delivery system is characterized by small-scale facilities that handle deliveries in a decentralized manner with localized networks. According to the Japanese 2017 vital statistics of the Ministry of Health, Labour, and Welfare, deliveries at hospitals and clinics (i.e., facilities with <20 beds) account for 54.3% and 45.7% of all deliveries, respectively. Considering that approximately 31% of all cesarean deliveries are performed in clinics [3], obstetric research focusing on only hospital-level facilities does not accurately reflect the current state of the clinical practice of cesarean delivery.

The modes of anesthesia for cesarean delivery can be classified into two main categories: general and neuraxial anesthesia. Given the risks of difficult tracheal intubation, hypoxemia, aspiration, and accidental awareness, general anesthesia should be avoided in cesarean deliveries unless clinically indicated [4,5]. In the United States (US), the rate of general anesthesia use between 2010 and 2015 was 5.8% for all cesarean deliveries and 14.6% for emergency cases [6]. As there is a limited database that could be used to investigate the current state of the clinical practice of cesarean delivery, only a few studies address...
the rate of general anesthesia use in Japan. To date, therefore, the current status of general anesthesia use across Japanese medical facilities in real-world settings remains unclear.

In the Japanese insurance system, the definition of general anesthesia can be problematic. General anesthesia is coded as L008: “general anesthesia used in a closed-circuit system maintained by mask or mechanical ventilation” (Table S1). This definition does not necessarily require airway-securing devices; the definition of general anesthesia includes the administration of a general anesthesia agent for $\geq 20$ min in combination with oxygen or oxygen/nitrous oxide mixed gas by mask or endotracheal intubation. For example, neuraxial anesthesia administered in combination with intravenous sedation and oxygen supplementation via mask may be misclassified and claimed as general anesthesia, depending on an institutional or organizational policy.

The aim of this study was to investigate general anesthesia use for cesarean delivery over 15 years and to analyze the general anesthesia practice in Japan.

2. Materials and Methods

2.1. Data Source

This retrospective cohort study was approved by the Institutional Review Boards of Mie University and Fujita Health University (study approval numbers: H2019-167 and HM21-369, respectively). The requirement for additional informed consent from the patients was waived owing to the anonymous nature of the data. This study was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology Statement [7].

The medical claims data for this study were obtained from a medical database vendor (JMDC Co. Ltd., Tokyo, Japan) [8]. The JMDC database accumulates the reimbursement data of over 100 million insured persons from 2005, which represent approximately 10% of the Japanese population. This insurance-based database is suitable for maternal healthcare research because it collects claims data from over 250 health insurance associations whose enrollees are employees of medium-to-large companies and their family members. The JMDC database can provide comprehensive tracking data of outpatient and inpatient maternal patients chronologically, regardless of whether maternal patients visit the emergency department or require hospitalization. The database contains the following information: patient demographic data (e.g., age and sex), inpatient and outpatient claims data (e.g., medical and pharmacy claims for diagnosis, procedure, and medication), and facility information. Clinical diagnoses are coded according to the International Classification of Diseases 10th revision (ICD-10), procedural information is defined using Japanese standardized procedure codes (K codes), and medication information is coded according to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification system [9]. The quality of the data collected within the Japanese administrative data is generally guaranteed [10].

2.2. Study Population

Using the original Japanese K codes, we identified cesarean deliveries performed between 1 January 2005, and 31 March 2020, as follows: K898-2 for elective cesarean delivery, K898-1 for emergency cesarean delivery, and K898-3 (this procedure code was only used between 2010 and 2016) for cesarean delivery with placenta previa or preterm birth (i.e., birth before 32 weeks of gestation) [11]. Cases with missing anesthesia records were excluded from this study. Of the overall cesarean delivery cohort (general and neuraxial anesthesia cases), only cesarean deliveries with general anesthesia claim (L008) were analyzed (general anesthesia claim cohort).

2.3. Patient- and Facility-Level Variables

We assessed the following patient characteristics: age, Maternal Comorbidity Index (MCI), Charlson Comorbidity Index (CCI), and obstetrical/maternal/fetal risk factors associated with increased likelihood of general anesthesia use based on a previous study [12].
(e.g., amniotic fluid embolism, chorioamnionitis, fetal distress, obstetric hemorrhage, placental abruption, placenta accreta, placental dysfunction, umbilical cord prolapse, and uterine rupture) (Table S2). To determine the presence of specific comorbidities, we used the diagnostic ICD-10 codes, MCI developed by Bateman et al. [13], and CCI [14]. MCI is a validated scoring system for obstetric populations that is designed to assess maternal comorbidity [15,16].

Data on medical facilities included the number of beds (0–19, 20–99, 100–199, 200–299, 300–499, or >499 beds), facility characteristics, and payment system. We classified the facilities according to their characteristics into academic hospitals and non-academic hospitals [9]. We used the Diagnosis Procedure Combination (DPC) payment system as a surrogate for acute care hospitals.

2.4. Outcomes

The primary endpoint was the prevalence of general anesthesia use. We used the following two definitions of general anesthesia: (1) insurance definition and (2) clinical definition. In general, general anesthesia was coded as L008 in the database (“insurance definition”). However, given that, in the Japanese health insurance system, the clinical anesthesia definition differs from the insurance definition, we developed second definitions of general anesthesia by combining the Japanese L008 codes and WHO-ATC drug claims. Rapid sequence induction (RSI) with securing of the airway is the standard induction technique for cesarean delivery under general anesthesia [5]. A previous study has revealed that RSI was the preferred induction method for women undergoing obstetric surgery in England, and neuromuscular blocking agents (NMBAs) were used in 98% of cases [17]. Therefore, as “clinical definition” of general anesthesia, we defined general anesthesia as the combination of L008 and use of an NMA (WHO-ATC drug code: M03) to avoid misclassification, regardless of whether regional block was performed.

2.5. Statistical Analysis

Patient, medical facility, and medication characteristics were assessed for cases with and without NMBAs. Continuous variables were presented as mean and standard deviation (SD) or as median and interquartile range (IQR), and categorical variables were presented as numbers and percentages. In general, the larger the sample size, the smaller the \( p \)-value obtained from the data for the baseline comparison. Therefore, we calculated the standardized mean difference (SMDs) between L008 cases with and without NMBAs; an absolute SMD > 10% indicates meaningful imbalance between group differences [18]. We calculated the proportions of general anesthesia use for the entire cohort and described the trend of general anesthesia practice for cesarean deliveries from 2005 to 2020. The rate of general anesthesia use was calculated yearly and stratified according to the general anesthesia definition (i.e., insurance and clinical anesthesia definitions). The trends of proportions were assessed using the Cochran–Armitage trend test [19].

All analyses were performed using SAS 9.4 for Windows (SAS Institute Inc., Cary, NC, USA).

3. Results

3.1. Study Cohort

Figure 1 shows the flow diagram. In the initial cohort of patients, 77,640 cesarean deliveries were considered eligible procedures; of these, we excluded 1460 procedures owing to missing anesthesia information. Thus, an overall cohort of 76,180 procedures involving 64,761 women at 2506 institutions between 1 January 2005, and 31 March 2020, were included in the analysis. After the exclusion of neuraxial anesthesia cases (85.6%, \( n = 65,208 \)), the general anesthesia claim cohort defined by the L008 code included 10,108 patients who underwent 10,972 cesarean deliveries at 1111 institutions. Of the general anesthesia claim cohort (L008), the mean patient age (standard deviation) was 33.2 (5.0) years, there were 4301 emergency operations (39.2%), and 41.6% of the cesarean
deliveries were performed in facilities with <20 beds. NMBAs were used in only 27.3% of the general anesthesia claim cohort (n = 2992).

**Figure 1.** Flow diagram.

### 3.2. Patient and Medical Facility Characteristics

Table 1 summarizes the patient demographic and facility characteristics of the study population who did and did not receive NMBAs. The group who received NMBAs was more likely to have obstetrical comorbidities and a higher burden than the group who did not receive NMBAs. The obstetrical/maternal/fetal risk factors were more likely to occur in the group who received NMBAs than in those who did not. The group who received NMBAs was more likely to undergo emergency cesarean deliveries in a larger medical facility, especially >499 bed size, academic hospitals, and DPC payment system hospitals (Table 1).

**Table 1.** Patient and medical facility characteristics of the study cohort with general anesthesia claim code (L008) according to the use of neuromuscular blocking agents (NMBAs).

| Characteristic                        | L008 with NMBA, n = 2992 | L008 without NMBA, n = 7980 | Absolute SMD (%) |
|--------------------------------------|--------------------------|-----------------------------|------------------|
| Age, year                            | 33.4 ± 5.1               | 33.1 ± 4.9                  | 5.0              |
| Mean ± SD                            | 1826 (61.0)              | 5060 (63.4)                 | 4.9              |
| <35                                  | 266 (8.9)                | 616 (7.7)                   | 4.2              |
| 35–39                                | 31 (1.0)                 | 63 (0.8)                    | 2.6              |
| Maternal Comorbidity Index           |                          |                             |                  |
| Alcohol abuse                        | 2 (0.1)                  | 2 (0.0)                     | 1.9              |
| Asthma                               | 241 (8.1)                | 616 (7.7)                   | 1.2              |
| Cardiac valvular disease             | 23 (0.8)                 | 16 (0.2)                    | 8.2              |
| Chronic congestive heart failure     | 5 (0.2)                  | 1 (0.0)                     | 5.2              |
| Chronic ischemic heart disease       | 32 (1.1)                 | 27 (0.3)                    | 8.8              |
| Chronic renal disease                | 26 (0.9)                 | 26 (0.3)                    | 7.1              |
| Congenital heart disease             | 24 (0.8)                 | 15 (0.2)                    | 8.8              |
| Drug abuse                           | 0 (0)                    | 0 (0)                       |                  |
| Gestational hypertension             | 32 (1.1)                 | 51 (0.6)                    | 4.7              |
| Human immunodeficiency virus         | 0 (0)                    | 0 (0)                       |                  |
| Mild/unspecified pre-eclampsia       | 113 (3.8)                | 246 (3.1)                   | 3.8              |
| Multiple gestation                   | 120 (4.0)                | 198 (2.5)                   | 8.6              |
| Placenta previa                      | 270 (9.0)                | 374 (4.7)                   | 17.2             |
| Pre-existing diabetes mellitus       | 41 (1.4)                 | 40 (0.5)                    | 9.0              |
| Pre-existing hypertension            | 88 (2.9)                 | 106 (1.3)                   | 11.2             |
| Previous cesarean delivery           | 193 (6.5)                | 938 (11.8)                  | 18.5             |
Table 1. Cont.

| Characteristic                                                                 | L008 with NMBA, n = 2992 | L008 without NMBA, n = 7980 | Absolute SMD (%) |
|-------------------------------------------------------------------------------|--------------------------|-----------------------------|------------------|
| Pulmonary hypertension                                                        | 4 (0.1)                  | 0 (0)                       | 5.2              |
| Severe pre-eclampsia                                                          | 111 (3.7)                | 246 (3.1)                   | 3.5              |
| Sickle cell disease                                                           | 0 (0)                    | 0 (0)                       |                  |
| Systemic lupus erythematosus                                                  | 21 (0.7)                 | 13 (0.2)                    | 8.2              |
| Maternal Comorbidity Index score, median (IQR)                                | 1 (0–2)                  | 1 (0–1)                     |                  |
| 0                                                                             | 1298 (43.4)              | 3767 (47.2)                 | 7.7              |
| 1–2                                                                           | 1237 (41.3)              | 3407 (42.7)                 | 2.7              |
| >2                                                                            | 457 (15.3)               | 806 (10.1)                  | 15.6             |
| Obstetrical/maternal/fetal emergency                                          |                         |                             |                  |
| Amniotic fluid embolism                                                       | 8 (0.3)                  | 0 (0)                       | 7.3              |
| Chorioamnionitis                                                              | 287 (9.6)                | 418 (5.2)                   | 16.7             |
| Fetal distress                                                                | 675 (22.6)               | 1260 (15.8)                 | 17.3             |
| Obstetric hemorrhage                                                          | 8 (0.3)                  | 8 (0.1)                     | 3.9              |
| Placental abruption                                                           | 375 (12.5)               | 87 (1.1)                    | 46.6             |
| Placenta accreta                                                              | 51 (1.7)                 | 27 (0.3)                    | 13.6             |
| Placental dysfunction                                                         | 353 (11.8)               | 476 (6.0)                   | 20.6             |
| Umbilical cord prolapse                                                       | 70 (2.3)                 | 102 (1.3)                   | 8.0              |
| Uterine rupture                                                               | 20 (0.7)                 | 12 (0.2)                    | 8.1              |
| Type of cesarean delivery                                                     |                         |                             |                  |
| Elective (K898-2)                                                             | 1093 (36.5)              | 5343 (67.0)                 | 63.9             |
| Emergency (K898-1)                                                            | 1726 (57.7)              | 2575 (32.3)                 | 52.8             |
| Cesarean delivery with placenta previa or preterm birth (K898-3) *           | 173 (5.8)                | 62 (0.8)                    | 28.4             |
| Fiscal year                                                                   |                         |                             |                  |
| 2005–2009                                                                     | 231 (7.7)                | 626 (7.8)                   | 0.5              |
| 2010–2014                                                                     | 874 (29.2)               | 2588 (32.4)                 | 7.0              |
| 2015–2020                                                                     | 1887 (63.1)              | 4766 (59.7)                 | 6.9              |
| Number of beds                                                                |                         |                             |                  |
| 0–19                                                                         | 520 (17.4)               | 4047 (50.7)                 | 75.1             |
| 20–99                                                                        | 346 (11.6)               | 1429 (17.9)                 | 18.0             |
| 100–199                                                                      | 48 (1.6)                 | 227 (2.8)                   | 8.4              |
| 200–299                                                                      | 81 (2.7)                 | 358 (4.5)                   | 9.6              |
| 300–499                                                                      | 419 (14.0)               | 1152 (14.4)                 | 1.2              |
| >499                                                                         | 1578 (52.7)              | 767 (9.6)                   | 105.2            |
| Academic hospital                                                             | 656 (21.9)               | 174 (2.2)                   | 63.6             |
| DPC payment system hospital                                                   | 2109 (70.5)              | 2380 (29.8)                 | 89.0             |

Values given as frequencies (%) unless stated otherwise. Absolute SMD > 10% indicates meaningful imbalance between group differences. DPC, Diagnostic Procedure Combination; IQR, interquartile range; NMBA, neuromuscular blocking agents; SD, standard deviation; SMD, standardized mean difference. * Procedure code only available from 2010 to 2016.

Table 2 presents a comparison of intraoperative drugs used in the study cohort with general anesthesia claim code (L008) according to the use of NMBA. The NMBA used for RSI were rocuronium (in 78.5% of cases) and suxamethonium (in 33.9% of cases). The use of vecuronium and pancuronium is not recommended for RSI for cesarean delivery owing to the slow onset of action; therefore, these drugs were probably used in an addition to the fast-acting suxamethonium. Regarding general anesthetics, the group that received NMBA was more likely to receive propofol (62.0% vs. 42.9%), barbiturate (47.5% vs. 4.1%), and volatile halogenated agents (67.8% vs. 15.1%) compared to the group that did not receive NMBA. In contrast, benzodiazepine, nitrous oxide, and ketamine were more likely used in the group that did not receive NMBA. The group that received NMBA was also more likely to receive fentanyl (68.2% vs. 37.0%) and remifentanil (48.4% vs. 0.2%). Regarding the group that did not receive NMBA (7980 cases), spinal anesthesia was used in 63.9% of cases.
Table 2. Comparison of intraoperative drugs used in the study cohort with general anesthesia claim code (L008) according to the use of neuromuscular blocking agents (NMBAs).

|                     | L008 with NMBAs, n = 2992 | L008 without NMBAs, n = 7980 | Absolute SMD (%) |
|---------------------|--------------------------|----------------------------|------------------|
| NMBAs *             | 2992 (100)               | 0 (0)                      | 270.3            |
| Rocuronium          | 2349 (78.5)              | 0 (0)                      | 101.2            |
| Suxamethonium       | 1014 (33.9)              | 0 (0)                      | 47.0             |
| Vecuronium          | 298 (10.0)               | 0 (0)                      | 15.6             |
| Pancuronium         | 36 (1.2)                 | 0 (0)                      |                  |
| Anesthetics         |                          |                            |                  |
| Propofol            | 1855 (62.0)              | 3425 (42.9)                | 38.9             |
| Barbiturate         | 1422 (47.5)              | 326 (4.1)                  | 114.3            |
| Benzodiazepine      | 391 (13.1)               | 1487 (18.6)                | 15.3             |
| Volatile halogenated agents | 2030 (67.8) | 1202 (15.1)                | 126.9            |
| Nitrous oxide       | 1237 (41.3)              | 5064 (63.5)                | 45.4             |
| Ketamine            | 212 (7.1)                | 791 (9.9)                  | 10.1             |
| Analgesics          |                          |                            |                  |
| Fentanyl            | 2040 (68.2)              | 2951 (37.0)                | 65.8             |
| Remifentanil        | 1447 (48.4)              | 15 (0.2)                   | 135.8            |
| Morphine (any route)| 239 (8.0)                | 1171 (14.7)                | 21.2             |
| Local anesthetic for spinal anesthesia | 423 (14.1) | 5103 (63.9)                | 118.7            |
| Bupivacaine for spinal anesthesia | 410 (13.7) | 4637 (58.1)                | 104.4            |
| Local anesthetic for epidural anesthesia | 1032 (34.5) | 4463 (55.9)                | 44.1             |
| 2% Lidocaine        | 85 (2.8)                 | 602 (7.5)                  | 21.3             |
| 2% Mepivacaine      | 65 (2.2)                 | 1154 (14.5)                | 45.6             |
| Ropivacaine         | 728 (24.3)               | 3012 (37.7)                | 29.3             |
| LevoBupivacaine     | 232 (7.8)                | 378 (4.7)                  | 12.5             |
| Bupivacaine, excluding for spinal anesthesia | 46 (1.5) | 881 (11.0)                | 39.9             |
| Code L003: continuous infusion of local anesthetic after epidural anesthesia | 349 (11.7) | 3105 (38.9)                | 66.0             |

Values given as frequencies (%) unless stated otherwise. Absolute SMD > 10% indicates meaningful imbalance between group differences. NMBAs, neuromuscular blocking agents; SMD, standardized mean difference. * From 2005 to 2020, only rocuronium, vecuronium, pancuronium, and suxamethonium were available for clinical use in Japan.

3.3. Trends in the Rate of General Anesthesia Use

Figure 2 shows the longitudinal changes in general anesthesia use from 2005 to 2020 according to the general anesthesia definition (insurance and clinical definitions). The rates of general anesthesia use in the insurance definition in 2005, 2010, 2015, and 2020 were 29.5%, 22.5%, 12.9%, and 11.5%, respectively (p for trend < 0.001). The temporal trend of the clinical definition of general anesthesia also decreased gradually from 9.9% in 2005 and 4.7% in 2010 to 3.3% in 2020 (p for trend < 0.001) (Figure 2 and Table S3).

Regarding medical facilities, of all L008 claim cases, 41.6% of the cases (4567/10,972) were claimed in obstetric facilities with <20 beds. Furthermore, 88.6% (100–11.4) of L008 cases at obstetric facilities with <20 beds did not use NMBAs (Table 1 and Figure 3A). Figure 3B shows that the percentage of L008 cases with and without NMBAs is proportional to the facility’s bed size. The L008 code with NMBAs was claimed for 67.3% of cases in large facilities with >499 beds and 11.4% of cases in facilities with <20 beds.
Bupivacaine, excluding for spinal anesthesia 46 (1.5) 881 (11.0) 39.9
Code L003: continuous infusion of local anesthetic after epidural anesthesia 349 (11.7) 3105 (38.9) 66.0
Values given as frequencies (%) unless stated otherwise. Absolute SMD > 10% indicates meaningful imbalance between group differences. NMBAs, neuromuscular blocking agents; SMD, standardized mean difference. * From 2005 to 2020, only rocuronium, vecuronium, pancuronium, and suxamethonium were available for clinical use in Japan.

3.3. Trends in the Rate of General Anesthesia Use

Figure 2 shows the longitudinal changes in general anesthesia use from 2005 to 2020 according to the general anesthesia definition (insurance and clinical definitions). The rates of general anesthesia use in the insurance definition in 2005, 2010, 2015, and 2020 were 29.5%, 22.5%, 12.9%, and 11.5%, respectively (p for trend < 0.001). The temporal trend of the clinical definition of general anesthesia also decreased gradually from 9.9% in 2005 and 4.7% in 2010 to 3.3% in 2020 (p for trend < 0.001) (Figure 2 and Table S3).

Figure 2. Annual rates of general anesthesia claim code (L008) with and without neuromuscular blocking agents (NMBAs) in total cesarean delivery cases from 2005 to 2020.

Regarding medical facilities, of all L008 claim cases, 41.6% of the cases (4567/10,972) were claimed in obstetric facilities with <20 beds. Furthermore, 88.6% (100–11.4) of L008 cases at obstetric facilities with <20 beds did not use NMBAs (Table 1 and Figure 3A).

Figure 3B shows that the percentage of L008 cases with and without NMBAs is proportional to the facility's bed size. The L008 code with NMBAs was claimed for 67.3% of cases in large facilities with >499 beds and 11.4% of cases in facilities with <20 beds.

4. Discussion

In this study, we identified the current epidemiology of general anesthesia for cesarean delivery in real-world setting in Japan and the inherent problems of these reimbursements. This information is important to understand, guide future study, and inform not only physicians but also policymakers in Japan. Our results showed a temporal trend of gradual decrease in general anesthesia use, regardless of its definition. The majority of L008 cases at obstetric facilities with <20 beds did not receive NMBAs. Our study strongly suggests that 72.7% of general anesthesia cases with the insurance definition cannot be clinically defined as general anesthesia.

Our analysis revealed that the rate of general anesthesia use for cesarean delivery ranged from 3.9% in clinical definition to 14.4% in insurance definition. The rate of general anesthesia use can be used as a quality indicator to support the monitoring of local performance and its improvement. In the quality improvement compendium, the Royal College of Anaesthetists raised the standards of quality indicators of care to >95% for elective anesthesia.
4. Discussion

In this study, we identified the current epidemiology of general anesthesia for cesarean delivery in real-world setting in Japan and the inherent problems of these reimbursements. This information is important to understand, guide future study, and inform not only physicians but also policymakers in Japan. Our results showed a temporal trend of gradual decrease in general anesthesia use, regardless of its definition. The majority of L008 cases at obstetric facilities with <20 beds did not receive NMBAs. Our study strongly suggests that 72.7% of general anesthesia cases with the insurance definition cannot be clinically defined as general anesthesia.

Our analysis revealed that the rate of general anesthesia use for cesarean delivery ranged from 3.9% in clinical definition to 14.4% in insurance definition. The rate of general anesthesia use can be used as a quality indicator to support the monitoring of local performance and its improvement. In the quality improvement compendium, the Royal College of Anaesthetists raised the standards of quality indicators of care to >95% for elective cesarean deliveries performed under neuraxial anesthesia and to >85% for emergency cases [20]. Our study demonstrated that the temporal trend of general anesthesia with the clinical definition decreased gradually from 9.9% in 2005 to 3.3% in 2020, which is consistent with the finding of a US study that revealed a national trend of decrease in the rate of general anesthesia use from 13.2% in 2010 to 2.6% in 2015 [6]. A previous survey of a 30-year obstetric anesthesia workforce in the US also revealed a constant low rate of elective general anesthesia use but a slight increase in the rate of emergency cases [21]. Czech and Slovak national surveys revealed an increase in the use of neuraxial anesthesia, but the proportion of general anesthesia remained high (24%) [22]. Our data can act as a benchmark when international data are compared to current obstetric anesthesia practice in Japan.

In the study by Abe et al., general anesthesia was used in 11.3% of elective cesarean deliveries from 2010 to 2013 [11]; this rate is significantly higher than in our study’s general anesthesia cases with the clinical definition and in the cases of previous studies conducted in high-income countries [23]. The high rate of general anesthesia use in the study by Abe et al. is explained partially by the characteristics of the database used in their study, especially as the database mainly contains data from acute care hospitals and high-volume centers in Japan (in the setting of DPC hospitals). In a retrospective review of 10-year trends in general anesthesia practice for cesarean delivery at a university hospital (i.e., DPC hospitals) in Japan, they reported a steady decline in the percentage of elective cesarean deliveries performed under general anesthesia from 11.1% in 2010 to 4.4% in 2019 [24]. However, 31% of cesarean deliveries are also performed in small facilities in Japan [3]; thus, a study that focuses only on hospital-level facilities does not accurately reflect current obstetrics anesthesia practice in Japan. Moreover, Japanese anesthesia-related codes (L code) are the basis for the determination of the type of anesthesia; therefore, coding accuracy or miscoding can lead to misclassification bias. Considering the difficulty associated with identifying general anesthesia using only anesthesia claims codes, the problem of reimbursement may explain the overestimation of the rate of general anesthesia use in the previous Japanese study on cesarean delivery [11]. In fact, our study results show that regarding the L008 cases without NMBAs, the administration of general anesthetics, such as propofol, barbiturate, volatile agents, and remifentanil, was disproportionately low compared to the L008 cases with NMBAs (clinical definition of general anesthesia). This reimbursement problem may explain the overestimation of the rate of general anesthesia use in the study [11]. Our data strongly suggest that 72.7% of the general anesthesia cases with the insurance definition cannot be clinically defined as general anesthesia. We recommend the clinical definition of general anesthesia as the combination of L008 code and the use of NMBAs in a claimed-based approach.

Among the general anesthesia claim cohort (L008), 41.6% were claimed in obstetric facilities with <20 beds. Small facilities do not meet the standards of regular operating rooms as proposed by the European minimum standards and WHO [25,26]. Small facilities
do not have sufficient equipment (operating rooms), resources (drug availability), and work forces (anesthesiologists and neonatologists). Resuscitation may be difficult without adequate in-house neonatologists when an anesthetized baby is delivered after general anesthesia. Therefore, our study revealed potential barriers to improving maternal and neonatal safety and standardizing obstetrical anesthesia practice.

We cannot investigate why the majority (88.6%) of cesarean deliveries at small facilities (also known as “clinics”) did not use NMBAs, but they requested reimbursement in general anesthesia claims (L008) in our database. One possible explanation is that the “general anesthesia” itself in the health insurance system is vaguely defined. In terms of insurance reimbursement, general anesthesia reimbursement is 7 times higher than that of neuraxial anesthesia (Table S1), which may lead to incentives for small facilities, especially private obstetrical clinics.

The strength of our study is that it is the largest nationwide study to include diverse facilities and reflects the current state of clinical practice to date. The JMDC database is limited to the employee-based insured population; however, the Japanese health care system has universal health coverage. Hence, different types of health insurance or racial/social-economic disparities would not influence our results. Thus, our findings are likely indicative of the majority of cesarean deliveries performed in Japan [9].

The limitations of this study include the use of a claims-based database, which does not include indications for general anesthesia and potential confounding factors. Our claims-based database does not distinguish between the conversion from failed neuraxial anesthesia to general anesthesia and the combined use of general and neuraxial anesthesia. Cases of L008 with NMBAs could include conversion or concomitant use; however, it is impossible to distinguish between the two retrospectively. Second, coding inconsistencies or misclassification can affect our definition of general anesthesia. To avoid misclassification, we developed the clinical definition of general anesthesia as the combination of L008 code and the use of NMBAs. In a recent study, NMBAs were administered in more than 98% of cases of general anesthesia in women undergoing obstetric surgery in England [17]. Future validation studies of our definition of general anesthesia are warranted.

5. Conclusions

Identifying the current epidemiology of general anesthesia for cesarean delivery and inherent problems of reimbursements in Japan is important to understand, guide future study, and inform not only physicians but also policymakers. Our analysis revealed that the rate of general anesthesia use for cesarean delivery ranged from 3.9% to 14.4% of all cesarean deliveries depending on the definition. NMBAs were used in only 27.3% of L008 cases. We recommend the clinical definition of general anesthesia as the combination of L008 code and the use of NMBAs in a claims-based approach. Future validation studies of our claims-based approach to identify the general anesthesia practice are warranted.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11164808/s1, Table S1: List of all anesthesia-related codes; Table S2: List of all ICD-10 code definitions of clinical indications for general anesthesia; Table S3: Trend in general anesthesia use from 2005 to 2020 according to insurance and clinical definitions.

Author Contributions: Conceptualization: H.Y., Y.M. and S.N.; methodology: H.Y., Y.M. and S.N.; software, H.Y.; validation: Y.M. and S.N.; formal analysis: H.Y.; investigation: H.Y.; resources: H.Y. and H.T.; data curation: H.Y.; writing—original draft preparation: H.Y.; writing—review and editing: H.Y., Y.M., S.N., H.T. and M.S.; visualization: H.Y.; supervision: Y.M., H.T. and M.S.; project administration: H.Y.; funding acquisition: H.Y. All authors have read and agreed to the published version of the manuscript.

Funding: Funding: This research was supported by JSPS Grant-in-Aid for Scientific Research, grant number JP20K17834.
Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Fujita Health University (protocol code HM21-369, 16 December 2021).

Informed Consent Statement: The requirement for obtaining informed consent from the patients was not required due to the anonymous nature of the data.

Data Availability Statement: The datasets analyzed in this study are available from the corresponding author on reasonable request.

Acknowledgments: This work was supported by JSPS KAKENHI [Grant Number JP20K17834]. The authors thank the staff at JMDC Co., Ltd., Tokyo, Japan, for assistance with data preparation.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Hasegawa, J.; Katsuragi, S.; Tanaka, H.; Kurasaki, A.; Nakamura, M.; Murakoshi, T.; Nakata, M.; Kanayama, N.; Sekizawa, A.; Isamu, I.; et al. Decline in Maternal Death Due to Obstetric Haemorrhage between 2010 and 2017 in Japan. Sci. Rep. 2019, 9, 11026. [CrossRef]
2. Maeda, E.; Ishihara, O.; Tomio, J.; Miura, H.; Kobayashi, Y.; Terada, Y.; Murata, K.; Nomura, K. Cesarean Delivery Rates for Overall and Multiple Pregnancies in Japan: A Descriptive Study Using Nationwide Health Insurance Claims Data. J. Obstet. Gynaecol. Res. 2021, 47, 2099–2109. [CrossRef]
3. Survey of Medical Institutions. Available online: https://www.mhlw.go.jp/toukei/saikin/hw/iryosd/17/dl/02sisetu29-3.pdf (accessed on 14 January 2022).
4. Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and Perinatal Medicine. Anesthesiology 2016, 124, 270–300. [CrossRef]
5. Ring, L.; Landau, R.; Delgado, C. The current role of general anesthesia for cesarean delivery. Curr. Anesthesiol. Rep. 2021, 11, 18–27. [CrossRef]
6. Juang, J.; Gabriel, R.A.; Dutton, R.P.; Palanisamy, A.; Urman, R.D. Choice of anesthesia for cesarean delivery: An analysis of the national anesthesia clinical outcomes Registry. Anesth. Analg. 2017, 124, 1914–1917. [CrossRef]
7. Vandenbroucke, J.P.; von Elm, E.; Altman, D.G.; Gotzsche, P.C.; Mulrow, C.D.; Pocock, S.J.; Poole, C.; Schlesselman, J.J.; Egger, M. STROBE Initiative Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. Epidemiology 2007, 18, 835–838. [CrossRef]
8. Kimura, S.; Sato, T.; Ikeda, S.; Noda, M.; Nakayama, T. Development of a database of health insurance claims: Standardization of disease classifications and anonymous record linkage. J. Epidemiol. 2010, 20, 413–419. [CrossRef]
9. Yonekura, H.; Seto, K.; Ide, K.; Kawasaki, Y.; Tanaka, S.; Nahara, I.; Takeda, C.; Kawakami, K. Preoperative blood tests conducted before low-risk surgery in Japan: A retrospective observational study using a nationwide insurance claims database. Anesth. Analg. 2018, 126, 1633–1640. [CrossRef]
10. Tamamura, H.; Moriwaki, M.; Horiguchi, H.; Kodan, M.; Fushimi, K.; Yasunaga, H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J. Epidemiol. 2017, 27, 476–482. [CrossRef]
11. Abe, H.; Sumitani, M.; Uchida, K.; Ikeda, T.; Matsu, H.; Fushimi, K.; Yasunaga, H.; Yamada, Y. Association between mode of anaesthesia and severe maternal morbidity during admission for scheduled caesarean delivery: A nationwide population-based study in Japan, 2010–2013. Br. J. Anesth. 2018, 120, 779–789. [CrossRef]
12. Guglielminotti, J.; Landau, R.; Li, G. Adverse events and factors associated with potentially avoidable use of general anesthesia in cesarean deliveries. Anesthesiology 2019, 130, 912–922. [CrossRef]
13. Bateman, B.T.; Myhre, J.M.; Hernandez-Diaz, S.; Huybrechts, K.F.; Fischer, M.A.; Creanga, A.A.; Callaghan, W.M.; Gagne, J.J. Development of a comorbidity index for use in obstetric patients. Obstet. Gynecol. 2013, 122, 957–965. [CrossRef]
14. Quan, H.; Sundararajan, V.; Halfon, P.; Fong, A.; Burnand, B.; Luthi, J.-C.; Saunders, L.D.; Beck, C.A.; Feasby, T.E.; Ghali, W.A. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care 2005, 43, 1130–1139. [CrossRef]
15. Aoyama, K.; D’Souza, R.; Inada, E.; Lapinsky, S.E.; Fowler, R.A. Measurement properties of comorbidity indices in maternal health research: A systematic review. BMC Pregnancy Childbirth 2017, 17, 372. [CrossRef]
16. Metcalfe, A.; Lix, L.M.; Johnson, J.-A.; Curnie, G.; Lyon, A.W.; Bernstein, F.; Tough, S.C. Validation of an obstetric comorbidity index in an external population. BJOG 2015, 122, 1748–1755. [CrossRef]
17. Odor, P.M.; Bampoe, S.; Moonesinghe, S.; Andrade, J.; Pandit, J.J.; Lucas, D.N. Pan-London Perioperative Audit and Research Network (PLAN), for the DREAMY Investigators Group General Anaesthetic and Airway Management Practice for Obstetric Surgery in England: A Prospective, Multicentre Observational Study. Anaesthesia 2021, 76, 460–471. [CrossRef]
18. Austin, P.C. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat. Simul. Comput. 2009, 38, 1228–1234. [CrossRef]
19. Guglielminotti, J.; Wong, C.A.; Landau, R.; Li, G. Temporal trends in anesthesia-related adverse events in cesarean deliveries, New York State, 2003–2012. Anesthesiology 2015, 123, 1013–1023. [CrossRef]
20. Raising the Standards: RCoA Quality Improvement Compendium. Available online: https://www.rcoa.ac.uk/safety-standards-quality/quality-improvement/raising-standards-rcoa-quality-improvement-compendium (accessed on 14 January 2022).

21. Traynor, A.J.; Aragon, M.; Ghosh, D.; Choi, R.S.; Dingmann, C.; Vu Tran, Z.; Bucklin, B.A. Obstetric anesthesia workforce survey: A 30-year update. Anesth. Analg. 2016, 122, 1939–1946. [CrossRef]

22. Stourac, P.; Kosinova, M.; Blaha, J.; Grochova, M.; Klozova, R.; Noskova, P.; Seidlova, D.; Richterova, S.; Firment, J.; OBAAMA-INT Study Group. Changes in Caesarean Section Anaesthesia between 2011 and 2015: Czech and Slovak National Surveys. Eur. J. Anaesthesiol. 2019, 36, 801–803. [CrossRef]

23. Butwick, A.J.; Palanisamy, A. Mode of anaesthesia for caesarean delivery and maternal morbidity: Can we overcome confounding by indication? Br. J. Anaesth. 2018, 120, 621–623. [CrossRef]

24. Ikeda, T.; Kato, A.; Bougaki, M.; Araki, Y.; Ohata, T.; Kawashima, S.; Imai, Y.; Ninagawa, J.; Oba, K.; Chang, K.; et al. A retrospective review of 10-year trends in general anesthesia for cesarean delivery at a university hospital: The impact of a newly launched team on obstetric anesthesia practice. BMC Health Serv. Res. 2020, 20, 421. [CrossRef]

25. Guasch, E.; Brogly, N.; Mercier, F.J.; Ioscovich, A.; Weiniger, C.F.; Lucas, N.; Chassard, D.; Kranke, P.; Whitaker, D.; Geldner, G.; et al. European minimum standards for obstetric analgesia and anaesthesia departments: An experts’ consensus. Eur. J. Anaesthesiol. 2020, 37, 1115–1125. [CrossRef]

26. Gelb, A.W.; Morriss, W.W.; Johnson, W.; Merry, A.F.; Gelb, A.W.; Merry, A.F.; Morriss, W.; Abayadeera, A.; Belii, N.; Brull, S.J.; et al. World Health Organization-World Federation of Societies of Anaesthesiologists (WHO-WFSA) International Standards for a Safe Practice of Anesthesia. Can. J. Anesth./J. Can. Anesth. 2018, 65, 698–708. [CrossRef]